Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
出版年份 2021 全文链接
标题
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-05-15
DOI
10.1016/s1470-2045(21)00090-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria
- (2019) C Mircea S Tesileanu et al. NEURO-ONCOLOGY
- DNA methylation-based classification of central nervous system tumours
- (2018) David Capper et al. NATURE
- cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
- (2018) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
- (2017) Martin J van den Bent et al. LANCET
- The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis
- (2017) Maarten M J Wijnenga et al. NEURO-ONCOLOGY
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).
- (2016) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing
- (2016) Hendrikus J. Dubbink et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors
- (2016) Pierre Bady et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets
- (2015) Felix Sahm et al. ACTA NEUROPATHOLOGICA
- Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial
- (2015) Hendrikus J. Dubbink et al. NEURO-ONCOLOGY
- Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH
- (2014) J. Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
- (2013) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
- (2012) Pierre Bady et al. ACTA NEUROPATHOLOGICA
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations
- (2011) Shani Mulholland et al. INTERNATIONAL JOURNAL OF CANCER
- IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
- (2010) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
- (2010) C. Houillier et al. NEUROLOGY
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
- (2009) Takuya Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- Analysis of the IDH1 codon 132 mutation in brain tumors
- (2008) Jörg Balss et al. ACTA NEUROPATHOLOGICA
- Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
- (2008) Walter Taal et al. CANCER
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started